# Gemini Cross-Vendor Method Review Report: Tom VP Return Study (Commit 80b0c19b)

- Task: `gemini-method-review-tom-vp-study-1031`
- Reviewer: Gemini Flash (Antigravity cross-vendor review)
- Date: 2026-10-31 (UTC)
- Primary artifact: `MyTradingSys/research/gemini_burn_2026-10-31/METHOD_REVIEW_TOM_VP_STUDY.md`

## Summary of Audit

A rigorous cross-vendor review of commit `80b0c19b` (`vp_return_to_value.py`, `PRE_REG.md`, `RESULT.md`, `results.json`) was conducted across look-ahead risks, selection effects, costing, sample sizes, and empirical claims:

1. **Look-Ahead**: NO ISSUE FOUND. Profile uses strictly $D-1$ (`vp_return_to_value.py:94`), ATR anchor uses the 1h bar closed at/before 00:00 UTC (`vp_return_to_value.py:99`), and return detection strictly evaluates bars after the event (`vp_return_to_value.py:53, 65`).
2. **Selection / Censoring**: TWO EDGE ISSUES IDENTIFIED:
   - Part B boundary bar censoring (`vp_return_to_value.py:58, 65`): when `e + n - 1 == len(c) - 1`, the acceptance bar is the final bar of the day. The slice `h[e + n:]` is empty, forcing `returned = False` despite being flagged as `applicable=True`.
   - Event bar return exclusion (`vp_return_to_value.py:53`): an intraday touch of POC during the breakout bar `e` is not credited as a return.
3. **Missing Cost**: NO ISSUE FOUND. Correctly declared as non-trading frequency count (`PRE_REG.md:5, 31`).
4. **Sample Size ($N$)**: NO ISSUE FOUND. DEV $N = 871$ events for Part A (SOURCED: `results.json`), $N \in [387, 603]$ for Part B; all exceed $N \ge 100$.
5. **Claims Outrunning Data**: NO ISSUE FOUND. Authors explicitly refute Tom's 70% claim (observed 57.2%, 95% CI: 53.9..60.7%, SOURCED: `RESULT.md:12`) and highlight that local placebos (|d| <= 1 ATR) perform identically to real value (-0.8 pp difference, SOURCED: `RESULT.md:14`).

Noticed: The study provides a model example of post-hoc transparency by reporting that near placebos behave identically to the real value area, properly circumscribing what looked like a +10.4 pp pooled edge.
